a news selectcompanieshealth

Roche Diagnósticos announces new antigen test and remains committed to fighting the pandemic

Roche announced that it had obtained the CE marking for its new rapid antigen test that allows the use of nasal samples.

The test will be available in mid-February 2021 in countries that accept the CE marking and will complement the already vast set of innovative solutions that have been on the market since the beginning of the pandemic.

The new rapid antigen test, which is intended for use by healthcare professionals, will allow the sample to be taken from the front of the nose, instead of the nasopharynx, resulting in a simplified and faster test procedure. This test method can help to reduce the general discomfort of the person with suspected infection, particularly children, the elderly, and/or people with disabilities.

In addition to being less invasive, the test will also provide patients with the option to self-collect their nasal sample under the supervision of a healthcare professional, thus contributing to the reduction of the need for physical contact, which will help to reduce the risk exposure of the health team to the virus.

“With this new solution, it will be possible to provide patients with a less invasive diagnostic experience. Rapid tests continue to play an important role in the fight against COVID-19, especially in places where laboratory tests are not available and where rapid results are needed, such as nursing homes, healthcare and schools,” says Thomas Schinecker, CEO of Roche Diagnostics.

This new diagnostic solution will be another important contribution to add to Roche’s diagnostic solutions portfolio to help healthcare systems fight COVID-19.

Follow us on social media: Instagram; Facebook; Twitter; Youtube.

Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
error: Content is protected !!